Advertisement

Critical Illness Stress-induced Immune Suppression

  • J. A. Carcillo
Conference paper
  • 709 Downloads

Abstract

Despite the use of Centers for Disease Control and Prevention (CDC) recommended practices to minimize infection risk, nosocomial sepsis and multiple organ failure (MOF) remain a leading cause of morbidity and mortality in critically ill patients. It is well documented that the use of immunosuppressant therapies dramatically increases this risk in patients with cancer, transplantation, and immunologic disease. Although immune monitoring has yet to be universally embraced, withdrawal of immunosuppressant therapies and use of immune restoration therapies is the standard of care when these patients develop sepsis. Critical illness stress can also induce a level of immunosuppression which is as life-threatening as is seen in the purposefully immunosuppressed patient. This chapter reviews the role of critical illness stress-induced immunosuppression in the development of nosocomial sepsis and MOF, and outlines clinical strategies which can be employed to maintain and restore immune function, and reduce morbidity and mortality in critically ill patients.

Keywords

Critical Illness Calcineurin Inhibitor Drotrecogin Alfa Endotoxin Tolerance Solid Organ Transplant Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Satoh S, Oishi K, Iwagaki A, et al (2001) Dexamethasone impairs pulmonary defence against Pseudomonas Aeruginosa through suppressing iNOS gene expression and peroxynitrite production by mice Clin Exp Immunol 126:266–273PubMedCrossRefGoogle Scholar
  2. 2.
    Hurwitz CA, Silverman LB, Schorin MA, et al (2000) Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88:1964–1999PubMedCrossRefGoogle Scholar
  3. 3.
    Hirano T, Horigome A, Takatani M, Oka K (2001) Cortisone counteracts apoptosis inducing effect of cortisol in human peripheral blood mononuclear cells. Int Immunopharmacol 1:2109–2115PubMedCrossRefGoogle Scholar
  4. 4.
    Green DR, Beere HM (2000) Apoptosis. Gone but not forgotten. Nature 405:28–29PubMedCrossRefGoogle Scholar
  5. 5.
    Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA (2005) Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nososcomial sepsis and multiple organ failure. J Immunol 174:3765–3772PubMedGoogle Scholar
  6. 6.
    Volk HD, Reinke P, Docke WD (1999) Immunological monitoring of the inflammatory process: Which variables? When to assess? Eur J Surg Suppl (584):70–72PubMedCrossRefGoogle Scholar
  7. 7.
    Smith TJ, Khatcheressian J, Lyman GH, et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence based clinical pratcice guideline. J Clin Oncol 24:3187–3205PubMedCrossRefGoogle Scholar
  8. 8.
    Sparrelid E, Emanuel F, Fehninger T, Andersson U, Andersson J (1997) Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T cell mediated cytotoxicity. Transplantation 63:1782–1789PubMedCrossRefGoogle Scholar
  9. 9.
    Volk HD, Reinke P, Krausch D, et al (1996) Monocyte deactivation — rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22(Suppl 4):S474–481PubMedCrossRefGoogle Scholar
  10. 10.
    Hotchkiss RS Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813–822PubMedCrossRefGoogle Scholar
  11. 11.
    Chaudry IH, Samy TS, Schwacha MG, et al (2003) Endocrine targets in experimental shock. J Trauma 54(Suppl 5):S118–125PubMedGoogle Scholar
  12. 12.
    Mullner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G (2004) Vasopressors for shock. Cochrane Database Syst Rev CD003709Google Scholar
  13. 13.
    Millbrandt EB, Kersten A, Kong L, et al (2005) Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med 33:226–229CrossRefGoogle Scholar
  14. 14.
    Brooks WA, Yunus M, Santosham M, et al (2004) Zinc for severe pneumonia in very young children: double blind placebo controlled trial. Lancet 363:1683–1688PubMedCrossRefGoogle Scholar
  15. 15.
    Darlow BA, Austin NC (2003) Selenium supplementation to prevent short term morbidity in pre term neonates. Cochrane Database Syst Rev CD003312Google Scholar
  16. 16.
    Hotchkiss RS, Chang KC, Grayson MH, et al (2003) Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 100:6724–6729PubMedCrossRefGoogle Scholar
  17. 17.
    Avdi NJ, Nick JA, Whitlock BB, et al (2001) Tumor necrosis factor alpha activation of the c-Jun N-terminal kinase pathway in human neutrophils. Integrin involvement in a pathway leading from cytoplasmic tyrosine kinases apoptosis. J Biol Chem 276:2189–2199PubMedCrossRefGoogle Scholar
  18. 18.
    Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW (2002) A randomized phase II trial of granulocyte macrophage colony stimulating factor therapy in severe sepsis with respiratory function. Am J Respir Crit Care Med 166:138–142PubMedCrossRefGoogle Scholar
  19. 19.
    Plotz FB, Vreugdenhil HA, Slutsky AS, et al (2002) Mechanical ventilation alters the immune response in children without lung pathology. Intensive Care Med 28:486–492PubMedCrossRefGoogle Scholar
  20. 20.
    Ranieri VM, Suter PM, Tortorella C, et al (1999) Effect of mechanical ventilation on inflammatory mediators in patients with acute respirtaory distress syndrome: a randomized controlled trial. JAMA 282:54–61PubMedCrossRefGoogle Scholar
  21. 21.
    The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301–1308CrossRefGoogle Scholar
  22. 22.
    Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A (2004) Innate immune response in TH1 and TH2 dominant mouse strains. Shock 22:460–468PubMedCrossRefGoogle Scholar
  23. 23.
    Wysocka M, Montaner LJ, Karp CL (2005) Flt 3 ligand treatment reverses endotoxin tolerance related immunoparalysis. J Immunol 174:7396–7402Google Scholar
  24. 24.
    Randow F, Docke WD, Bundschuh DS, et al (1997) In vitro prevention and reversal of lipopolysaccharide desensitization by IFN gamma, IL-12, and granulocyte macrophage colony stimulating factor. J Immunol 158:2911–2918PubMedGoogle Scholar
  25. 25.
    Bundshuh DS, Barsig J, Hartung T, et al (1997) Granulocyte macrophage colony stimulating factor and IFN gamma restore the systemic TNF alpha response to endotoxin in liposacchariade desensitized mice. J Immunol 158:2862–2871Google Scholar
  26. 26.
    Docke WD, Randow F, Syrbe U, et al (1997) Monocyte deactivation in septic patients: retsortaion by IFN-gamma treatment. Nat Med 3:678–681PubMedCrossRefGoogle Scholar
  27. 27.
    Rosenbloom AJ, Linden PK, Dottance A, et al (2005) Effect of granulocyte-monocyte colony stimulating factor therapy on leukocyte function and clearance of serious infection in non-neutropenic patients. Chest 127:2139–2150PubMedCrossRefGoogle Scholar
  28. 28.
    Barie PS, Williams MD, McCollam JS, et al (2004) Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 188:212–220PubMedCrossRefGoogle Scholar
  29. 29.
    Greeneltch KM, Kelly-Welch AE, Shi Y, Keegan AD (2005) Chronic morphine treatment promotes specific TH2 cytokine production by nurine T cells in vitro via a Fas/Fas ligand-dependent mechanisms. J Immunol 175:4999–5005PubMedGoogle Scholar
  30. 30.
    van den Berghe G, Wouters P, Weekers F, et al (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRefGoogle Scholar
  31. 31.
    Williams MD, Braun LA, Cooper LM, et al (2004) Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 8:R291–298PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media Inc. 2007

Authors and Affiliations

  • J. A. Carcillo
    • 1
  1. 1.Department of Critical Care MedicineChildren’s HospitalPittsburghUSA

Personalised recommendations